HSBC Holdings
BCRX icon

HSBC Holdings’s BioCryst Pharmaceuticals BCRX Stock Holding History

HSBC Holdings’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
109,320
+77,821
+247% +$704K ﹤0.01% 1905
2026
Q1 		$303K Buy
31,499
+7,366
+31% +$57.2K ﹤0.01% 2448
2025
Q4 		$188K Sell
24,133
-37,803
-61% -$273K ﹤0.01% 2702
2025
Q3 		$465K Sell
61,936
-10,527
-15% -$87.7K ﹤0.01% 2147
2025
Q2 		$656K Sell
72,463
-17,944
-20% -$167K ﹤0.01% 2009
2025
Q1 		$677K Buy
90,407
+346
+0.4% +$2.79K ﹤0.01% 1930
2024
Q4 		$677K Buy
90,061
+22,814
+34% +$173K ﹤0.01% 2007
2024
Q3 		$529K Sell
67,247
-57,757
-46% -$439K ﹤0.01% 1981
2024
Q2 		$759K Buy
125,004
+30,788
+33% +$170K ﹤0.01% 1783
2024
Q1 		$479K Buy
94,216
+73,181
+348% +$412K ﹤0.01% 2126
2023
Q4 		$127K Buy
21,035
+2,160
+11% +$12.5K ﹤0.01% 2560
2023
Q3 		$134K Buy
+18,875
New +$136K ﹤0.01% 2504
2021
Q3 		– Sell
-15,463
Closed -$246K – 2978
2021
Q2 		$246K Buy
+15,463
New +$210K ﹤0.01% 2644
2021
Q1 		– Sell
-34,869
Closed -$260K – 2739
2020
Q4 		$260K Sell
34,869
-12,059
-26% -$62.2K ﹤0.01% 2662
2020
Q3 		$164K Sell
46,928
-84,844
-64% -$364K ﹤0.01% 2523
2020
Q2 		$628K Sell
131,772
-61,393
-32% -$245K ﹤0.01% 1687
2020
Q1 		$382K Buy
193,165
+182,192
+1,660% +$502K ﹤0.01% 1920
2019
Q4 		$38K Buy
+10,973
New +$27.6K ﹤0.01% 2981
2017
Q1 		– Sell
-12,654
Closed -$80K – 2154
2016
Q4 		$80K Buy
+12,654
New +$65.8K ﹤0.01% 2639

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

HSBC Holdings's BCRX Position: Q2 2026 in Review

HSBC Holdings increased its BioCryst Pharmaceuticals (BCRX) stake by 247% in Q2 2026, buying an estimated $704K and bringing the position to 109,320 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1905.

HSBC Holdings first reported a position in BCRX in Q4 2016 and has held it in 19 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • HSBC Holdings held 109,320 shares of BioCryst Pharmaceuticals worth $1.08M as of Q2 2026.
  • HSBC Holdings bought 77,821 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $704K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #1905 holding.
  • HSBC Holdings first reported a position in BioCryst Pharmaceuticals in Q4 2016 and has held it in 19 quarters since.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.